James Smith, DO
Cardiovascular Disease · Wichita, KSNPI 1619973906
Payments from drug & device makers
What this record shows
19 manufacturers reported payments, led by Abbott at 38.7% of the total. Reporting peaked in 2019 at $2,738 and has fallen 97.0% since, to $81 in 2025.
Across 88 payments — averaging $80.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Penumbra, Inc.$2K
- Philips North America LLC$954
- Abiomed$312
- Shockwave Medical, Inc$132
- AstraZeneca$125
- plus $696 from 13 others
What the payments were for
- Travel & lodging$2,91041%
- Food & beverage$4,21359%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $2,755 |
| Penumbra, Inc. | 6 | $2,148 |
| Philips North America LLC | 18 | $954 |
| Abiomed | 1 | $312 |
| Shockwave Medical, Inc | 1 | $132 |
| AstraZeneca | 8 | $125 |
| Bard Peripheral Vascular, Inc. | 2 | $120 |
| Jazz Pharmaceuticals Inc. | 1 | $99 |
| Boston Scientific | 2 | $96 |
| Boehringer Ingelheim | 2 | $96 |
| Johnson & Johnson | 5 | $75 |
| Lemaitre Vascular, Inc. | 1 | $54 |
| Medtronic | 1 | $53 |
| Bardy Diagnostics, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUBY Coil$1,912
- Omnilink Elite vascular stent system$1,253
- IGT D Peripheral$387
- Impella$312
- PERCLOSE PROGLIDE$240
- Indigo System$150
- Perclose ProGlide suture mediated closure system$149
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$132
- Xience Sierra Coronary Stent System$103
- (4067) Tack Endo Sys BTK$101
How this compares
$7,123 in reported general payments places this provider in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $30,426 |
| FarxigaDapagliflozin Propanediol | 45 | $28,521 |
| XareltoRivaroxaban | 37 | $27,373 |
| Bumetanide | 116 | $2,957 |
| Spironolactone | 325 | $1,636 |
| ClopidogrelClopidogrel Bisulfate | 174 | $1,514 |
| Pentoxifylline | 53 | $693 |
| Rosuvastatin Calcium | 48 | $564 |
| Torsemide | 46 | $489 |
| Atorvastatin Calcium | 68 | $403 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 81 | $386 |
| Losartan Potassium | 72 | $362 |
| Allopurinol | 40 | $357 |
| Gabapentin | 34 | $344 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $30,42648 claims |
| AstraZenecaFarxiga | $125 | $28,52145 claims |
| Johnson & JohnsonXarelto | $75 | $27,37337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.